TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01744704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhNGF 0.5 µg/mL Sentinel
Description: In Part 0, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration in the study eye (right or left) according to the randomisation list to achieve the required dose level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhNGF 5 µg/mL Sentinel
Description: Part 0 represented a sentinel group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhNGF 20 µg/mL Sentinel
Description: In Part 0, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration in the study eye (right or left) according to the randomisation list to achieve the required dose level
Study: NCT03596515

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensory Integration
Description: Sensory Integration (SI) is a theory and framework conceptualized by Dr. Jean Ayres, a highly experienced occupational therapist, with its main objective as enhancing the brain's capacity to perceive and organize sensory information to produce a more normal, adaptive response; thus, to provide the foundation for mastering academic tasks.
Study: NCT01744704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhNGF 20 µg/mL Part A
Description: In Part A, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h on Day 1 to achieve the required fractionated single dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhNGF 60 µg/mL Part A
Description: In Part A, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h on Day 1 to achieve the required fractionated single dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhNGF 180 µg/mL Part A
Description: In Part A, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h on Day 1 to achieve the required fractionated single dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhNGF 20 µg/mL Part B
Description: In Part B, as planned 3 dose levels of rh-NGF or placebo eye drops were studied in a total of 40 healthy subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhNGF 60 µg/mL Part B
Description: In Part B, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h for 5 days to achieve the required multiple fractionated dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhNGF 180 µg/mL Part B
Description: In Part B, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h for 5 days to achieve the required multiple fractionated dose level.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Part A
Description: In Part A, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h on Day 1 to achieve the required fractionated single dose level.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Part B
Description: In Part B, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h for 5 days to achieve the required multiple fractionated dose level.
Study: NCT02209181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-10450232 / Not yet marketed
Description: Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-10450232 / Not yet marketed
Description: Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: JNJ-10450232 / Not yet marketed
Description: Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetaminophen / Tylenol
Description: Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.
Study: NCT01657747

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Whole body diffusion-weighted MRI
Description: MRI is a technique based on magnetic fields and does not require the use of ionizing radiation. Although there are no known side effects associated with MRI, a few precautions should be taken because of the 3T magnetic field. This implicates that all metal and magnetized objects must be removed from the patient before entering the MRI room. Patients with a pacemaker, a cardiac defibrillator or other implanted conductors/prostheses are for this reason not eligible for the study.~During the whole body MRI examination, an intravenous contrast agent will be administered. In most cases, patients do not experience any discomfort and the use of this contrast agent is part of the clinical routine.~During the whole body MRI examinations, a bowel relaxing injection (Buscopan) is also needed to reduce movement of the intestines.
Study: NCT00455897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Given 11 days before day 1 of cycle 1 for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP
Description: Administered as part of standard care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Administered as part of standard treatment
Study: NCT05996978

Intervention type: OTHER
Intervention: Intensive Drug Therapy
Description: Observational only and no predesigned interventions in this study
Study: NCT01137669

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated herpes zoster vaccine
Description: ZOSTAVAX® (Zoster Vaccine Live) is a live attenuated vaccine provided as a single-dose, sterile, lyophilized, preservative-free frozen formulation. The vaccine will be supplied in 3-mL glass vials. Sterile diluent will be used to reconstitute study vaccine. The reconstituted vial will be gently agitated to mix thoroughly. The entire contents of the reconstituted vaccine vial (approximately 0.65 mL) will be withdrawn into a syringe. The vaccine will be administered immediately subcutaneously in the deltoid region.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Zoster Vaccine Live (ZOSTAVAX®) is sterile normal saline which will be obtained from the Fisher Repository in single-dose containers. 0.9% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. The placebo will be administered subcutaneously in the deltoid region.
Study: NCT02630407

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: viscosupplementation
Description: A single 3 ml hyaluronic acid (HA) injection (viscosupplementation) performed the day after ACL reconstruction, after drainage removal

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: A single 3 ml saline injection performed the day after ACL reconstruction, after drainage removal
Study: NCT01562106

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluorescence-guided sentinel lymph node detection
Description: During standard endometrial cancer surgery, ICG dye will be injected into the cervix to identify sentinel lymph nodes in the pelvis.
Study: NCT01855711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GR68755 (Alosetron hydrochloride) 1 mg tablet
Description: 1 tablet (1 mg) once a day
Study: NCT01164111

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative resistance training
Description: preoperative resistance training: Duration 8 weeks. Intensity: 3 sets of 80 % of 1 repetition max (1 RM) in each exercise (stated as 8-10 repetitions of the exercise). Frequency: 2 times/week. The patient follows a special training program consisting of exercises with knee and hip extension. Training intensity is followed in a personalized log-book for each patient. Sessions are conducted in small teams closely supervised by specially trained physiotherapists.
Study: NCT00147277

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable Cardiac Defibrillator
Description: Medtronic Marquis Family ICD, capable of Anti Tachy Pacing (ATP) for Fast Ventricular Tachycardia (FVT) via Ventricular Fibrillation (VF) zone

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable Cardiac Defibrillator
Description: Medtronic Marquis Family ICD, capable of Anti Tachy Pacing (ATP) for Fast Ventricular Tachycardia (FVT) via Ventricular Fibrillation (VF) zone
Study: NCT04150536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine topical system 1.8%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine topical system 1.8%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine topical system 1.8%
Study: NCT00157027

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal photochemotherapy with UVADEX
Description: Photopheresis (or extracorporeal photoimmunetherapy \[ECP\]) is a process developed by THERAKOS, Inc., a Johnson and Johnson Company. During the process of ECP, whole blood is drawn from the patient over several cycles, centrifuged and separated into the components of plasma, white cells (or buffy coat), and red blood cells. A portion of the white cells and the plasma are saved in a separate compartment. The remaining plasma and red blood cells are immediately returned to the patient.~The saved buffy coat (white blood cells) and plasma are inoculated with the photosensitizing agent UVADEX. Photoactivation begins when the suspension is exposed to a prescribed amount of ultraviolet-A light. After photoactivation is complete, the treated suspension is returned to the patient.
Study: NCT00462605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entinostat
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given SC
Study: NCT02574325

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARI-3037MO
Description: Treatment
Study: NCT01181453

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermagraft
Description: Weekly application of Dermagraft(R) with standard care

Intervention type: OTHER
Group type: OTHER
Intervention: Comparator
Description: Weekly application of standard care
Study: NCT03576417

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Intravenous

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: RT
Description: IMRT 66 Gy / 6.5 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: RT
Description: IMRT 66 Gy / 6.5 weeks
Study: NCT02336100

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopy (FICE and pCLE)
Description: FICE is Flexible Spectral Imaging Color Enhancement and pCLE is probe-based Confocal Lase Endomicroscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopy (FICE and pCLE)
Description: FICE is Flexible Spectral Imaging Color Enhancement and pCLE is probe-based Confocal Lase Endomicroscopy
Study: NCT02531854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADXS11-001
Description: ADXS11-001 is a live attenuated Listeria monocytogenes (Lm) bacteria bioengineered to secrete an antigen-adjuvant fusion protein (tLLO¬HPV-E7) consisting of a truncated fragment of the listeriolysin O (tLLO) fused to the full length E7 peptide of HPV-16.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Chemotherapy
Study: NCT01867047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-I Cessation group
Description: Subjects stop ACE-I 48 hours prior to surgery. Examples of possible ACE-I drugs include:~benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec, Epaned), fosinopril (Monopril), lisinopril (Prinivil, Zestril), moexipril (Univasc), perindopril (Aceon), quinapril (Accupril), ramipril (Altace), trandolapril (Mavik)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-I Continuation group
Description: Subjects take ACE-I through day of surgery. Examples of possible ACE-I drugs include:~benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec, Epaned), fosinopril (Monopril), lisinopril (Prinivil, Zestril), moexipril (Univasc), perindopril (Aceon), quinapril (Accupril), ramipril (Altace), trandolapril (Mavik)
Study: NCT03614676

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sample collection
Description: Venous blood samples will be collected from the maternal subjects at Day 1 and Day 56 of the study and at delivery.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cord blood sample collection
Description: Collection of cord blood samples from maternal subjects will occur, at delivery

Intervention type: OTHER
Group type: OTHER
Intervention: Maternal Diary Card
Description: Completion of Diary Card about health by pregnant woman/ mother, from enrolment through week 6 post delivery.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Nasal Swab collection
Description: Collection of nasal swabs from infants with potential LRTIs, from birth to 12 months of age.

Intervention type: OTHER
Group type: OTHER
Intervention: Infant Diary Card
Description: Completion of Diary Card about health of infant from birth to 12 months of age.
Study: NCT01090011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: BIBW 2992 medium dose plus high dose level of cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: BIBW 2992 medium dose monotherapy, upon progression, cetuximab high dose is added

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: BIBW 2992 medium dose plus high dose level of cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: BIBW 2992 medium dose monotherapy, upon progression, cetuximab high dose is added
Study: NCT04578288

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: INDIVIDUALIZED BLOOD PRESSURE MANAGEMENT DURING ENDOVASCULAR TREATMENT OF ACUTE ISCHEMIC STROKE UNDER PROCEDURAL SEDATION
Description: The individual target range is defined as: bSBP ± 10 mmHg. The lowest possible SBP target range is 100-120 mmHg. The highest SBP target range is determined on the basis of whether patients receive concurrent IV fibrinolytic therapy or not. In patients where IV fibrinolytic therapy is applied, the highest SBP range is 160-180 mmHg, in patients without concurrent fibrinolytic therapy the highest SBP range is 180-200 mmHg.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: INDIVIDUALIZED BLOOD PRESSURE MANAGEMENT DURING ENDOVASCULAR TREATMENT OF ACUTE ISCHEMIC STROKE UNDER PROCEDURAL SEDATION
Description: The individual target range is defined as: bSBP ± 10 mmHg. The lowest possible SBP target range is 100-120 mmHg. The highest SBP target range is determined on the basis of whether patients receive concurrent IV fibrinolytic therapy or not. In patients where IV fibrinolytic therapy is applied, the highest SBP range is 160-180 mmHg, in patients without concurrent fibrinolytic therapy the highest SBP range is 180-200 mmHg.
Study: NCT02807974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-3150
Description: CS-3150 1.25 to 2.5, 5mg, orally
Study: NCT01857037

Intervention type: OTHER
Group type: OTHER
Intervention: Histoscanning™ and multiparametric MRI
Description: Detection and localization of prostate cancer local recurrences after radiation therapy using Histoscanning™ and multiparametric MRI
Study: NCT03455205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: shenqifuzheng
Description: 500ml shenqifuzheng daily（at day 1-7and day22-28）through intravenous infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9%sodium chloride
Description: 500ml sodium chloride（0.9%）daily（at day 1-7 and day22-28）through intravenous infusion.
Study: NCT01999972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: axitinib
Description: Axitinib: tablets, dosage range 2 - 5 mg, given orally twice daily on a continuous dosing schedule in 28 days cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib
Description: Crizotinib: capsules, dosage range 200-250 mg, given orally twice daily or every day on a continuous dosing schedule in 28 days cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: axitinib
Description: Axitinib: tablets, dosage be defined based on Arm 1 results, given orally twice daily on a continuous dosing schedule in 28 days cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib
Description: Crizotinib: capsules, dosage be defined based on Arm 1 results, given orally twice daily or every day on a continuous dosing schedule in 28 days cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: axitinib
Description: Axitinib: tablets, dosage be defined based on Arm 1 results, given orally twice daily on a continuous dosing schedule in 28 days cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib
Description: Crizotinib: capsules, dosage be defined based on Arm 1 results, given orally twice daily or every day on a continuous dosing schedule in 28 days cycle.
Study: NCT00785837

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquatic Physical Therapy
Description: The Physiotherapy was performed with gentle movements in eight shape, from left to right, in addition to movements of unbundling girdle, light and slow the trunk and extremities posture and body by flexing the organization Wrapping the body.
Study: NCT03038204

Intervention type: PROCEDURE
Intervention: The papillary muscle approximation
Description: Surgery is performed through median sternotomy, aortic and bicaval cannulation, normothermic perfusion, and antegrade cardioplegia with the use of cardioplegic solution.~After coronary anastomosis, the mitral valve is exposed by a transseptal incision.~The papillary muscles are approximated through the mitral valve at the level of papillary muscles heads. Nonabsorbable, braided sutures of 2-0 (Ethibond, Ethicon, Inc.) with PTFE felt pledgets are used for this purpose.~Annuloplasty mitral rings of different sizes are anchored using multiple deep U-shaped stitches of Ethibond 2-0 (Ethicon, Inc., USA). After MV repair, the LV is forcefully filled with saline water to test the valve competence. After satisfactory hydraulic test walls of the heart chambers are sutured.
Study: NCT00009906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Given orally
Study: NCT02250599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 175 mg/m2 IV Day 1 each 3-week cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 175 mg/m2 IV Day 1 each 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 7.5 mg/kg Day 1 each 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 6 IV Day 1 each 3-week cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC 6 IV Day 1 each 3-week cycle
Study: NCT03267810

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: TENS: TENS 7000 - : TENS applies low-level electrical current via four pads, 2 pads affixed paraspinally, at the level of the spinal cord injury, and 2 affixed on the ventral side to areas within the dermatome corresponding to the level of injury. 15 minutes of high frequency followed by 15 minutes of low frequency will be applied at each session

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham TENS
Description: Inactive electrodes - for two 15 minute trials, neither high nor low frequency.
Study: NCT02779348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 3-202
Description: Nebicapone tablets 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin
Description: Varfine® 5 mg (warfarin 5 mg) tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin
Description: Varfine® 5 mg (warfarin 5 mg) tablets
Study: NCT00502268

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxercalciferol administration
Description: Doxercalciferol administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxercalciferol administered by 1-84-7-84
Description: Doxercalciferol administered by 1-84-7-84
Study: NCT02738905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: One 550 mg tablet taken orally two times a day.
Study: NCT01986114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM-13496
Study: NCT03339271

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Technology-Enhanced Support
Description: The study nurse will meet with the caregiver daily until patient is discharged from the hospital. The caregiver will take home an iPad upon discharge, and will have an initial video chat with the study nurse within 24-48 hours of hospital discharge and weekly for 8 weeks after that.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Support
Description: The patient's doctor and nurses with input from the Palliative Care service will help the caregiver make a plan for discharge of the patient, and for taking care of the patient upon discharge. Someone from the study team will call the caregiver once a month for the duration of the study after the patient discharges from the hospital.